Does not prevent risk of transmission of HBV to others through sexual contact or contamination w/ blood. Closely monitor hepatobiliary & renal parameters in HBV infected patients w/ decompensated liver disease & Child Pugh Turcotte score >9 (ie, class C). Higher risk for hepatic decompensation following hepatitis exacerbation in patients w/ cirrhosis. Treatment discontinuation is not recommended in patients w/ advanced liver disease or cirrhosis. Nephrotoxicity. Patients coinfected w/ HBV & hepatitis C or D virus. HIV Ab testing to all HBV infected patients whose HIV-1 infection status is unknown before initiating therapy; co-administer w/ other antiretroviral agents in patients who are co-infected w/ HBV & HIV. Monitor hepatic function at repeated intervals w/ both clinical & lab follow-up for at least 6 mth after discontinuation of treatment for hepatitis B. Not to be co-administered w/ medicinal products containing tenofovir alafenamide, tenofovir disoproxil or adefovir dipivoxil. Not recommended w/ co-administration of P-gp inducers eg, anticonvulsants (eg, carbamazepine, oxcarbazepine, phenobarb & phenytoin), antimycobacterials (eg, rifampicin, rifabutin & rifapentine), & St John's wort; strong P-gp inhibitors eg, itraconazole & ketoconazole. Galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. Not recommended in patients w/ CrCl <15 mL/min who are not receiving haemodialysis. Do not use during lactation. Childn <12 yr or weighing <35 kg.
Sign Out
